UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Constitutional BRCA1 Epimutations: A Key for Understanding Basal‐Like Breast and High‐Grade Serous Ovarian Cancer

Human mutation, 2024-01, Vol.2024 (1)

2024

Volltextzugriff (PDF)

Interpreting plasma estrogen levels in breast cancer: caution needed

Journal of clinical oncology, 2014-05, Vol.32 (14), p.1396-1400

2014

Volltextzugriff (PDF)

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation

Journal of investigative dermatology, 2015-07, Vol.135 (7), p.1820-1828

2015

Volltextzugriff (PDF)

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Journal of clinical oncology, 2016-05, Vol.34 (14), p.1580-1583

2016

Volltextzugriff (PDF)

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

International journal of cancer, 2015-07, Vol.137 (1), p.96-103

2015

Volltextzugriff (PDF)

Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions

Annals of surgery, 2023-09, Vol.278 (3), p.e540-e548

2023

Volltextzugriff (PDF)

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

BMC cancer, 2012-01, Vol.12 (1), p.39-39, Article 39

2012

Volltextzugriff (PDF)

Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

Trends in Cancer, 2021-03, Vol.7 (3), p.181-185

Lønning, Per E

2021

Volltextzugriff (PDF)

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk

Annals of internal medicine, 2018-03, Vol.168 (5), p.326

2018

Volltextzugriff (PDF)

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

NMR in biomedicine, 2012-02, Vol.25 (2), p.369-378

2012

Volltextzugriff (PDF)

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

Oncotarget, 2011-03, Vol.2 (3), p.251-258

2011

Volltextzugriff (PDF)

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

Acta oncologica, 2014-10, Vol.53 (10), p.1347-1355

2014

Volltextzugriff (PDF)

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

Transcription, 2011-09, Vol.2 (5), p.207-210

2011

Volltextzugriff (PDF)

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Breast cancer research : BCR, 2018-10, Vol.20 (1), p.120-120, Article 120

2018

Volltextzugriff (PDF)

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

Oncotarget, 2017-06, Vol.8 (25), p.41227-41241

2017

Volltextzugriff (PDF)

Comment on "Towards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsies" by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, Lab Chip, 2017, 17, 1594

Lab on a chip, 2017-09, Vol.17 (18), p.3186-3187

Lønning, Per E

2017

Volltextzugriff (PDF)

Chemosensitivity and p53; new tricks by an old dog

Breast cancer research : BCR, 2012-11, Vol.14 (6), p.325-325, Article 325

2012

Volltextzugriff (PDF)

MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk

PloS one, 2012-04, Vol.7 (4), p.e36263-e36263

2012

Volltextzugriff (PDF)

Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?

Journal of clinical oncology, 2008-10, Vol.26 (30), p.4859-4861

Lønning, Per E

2008

Volltextzugriff (PDF)

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin

Biochimica et biophysica acta, 2013-03, Vol.1830 (3), p.2790-2797

2013

Volltextzugriff (PDF)

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

Scientific reports, 2021-12, Vol.11 (1), p.23463-23463, Article 23463

2021

Volltextzugriff (PDF)

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells

Translational oncology, 2017-10, Vol.10 (5), p.806-817

2017

Volltextzugriff (PDF)

Endocrine effects of aromatase inhibitors

Journal of clinical oncology, 2010-02, Vol.28 (6), p.e101-e102

2010

Volltextzugriff (PDF)

Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine

Journal of investigative dermatology, 2010-10, Vol.130 (10), p.2514-2516

2010

Volltextzugriff (PDF)

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

Breast cancer research : BCR, 2012-03, Vol.14 (2), p.R47-R47, Article R47

2012

Volltextzugriff (PDF)

1 – 25 von 179

Suche als RSS-Feed

Aktive Filter

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(157)

Publikationsform

Artikel
(178)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(144)
Life Sciences & Biomedicine
(139)
Humans
(137)
Female
(103)
Oncology
(88)
Breast Neoplasms - Drug Therapy
(68)
Biological And Medical Sciences
(45)
Middle Aged
(45)
Medical Sciences
(41)
Aged
(38)
Breast Cancer
(38)
Pharmacology. Drug Treatments
(35)
Antineoplastic Agents
(31)
Chemotherapy
(28)
Breast Neoplasms - Genetics
(27)
Adult
(26)
Aromatase Inhibitors
(25)
Antineoplastic Agents - Therapeutic Use
(22)
Breast Neoplasms - Metabolism
(21)
Breast Neoplasms - Pathology
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Constitutional BRCA1 Epimutations: A Key for Understanding Basal‐Like Breast and High‐Grade Serous Ovarian Cancer

Interpreting plasma estrogen levels in breast cancer: caution needed

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

Chemosensitivity and p53; new tricks by an old dog

MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk

Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells

Endocrine effects of aromatase inhibitors

Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

Aktive Filter

Suchergebnisse filtern